Research study Program year 2021 Source: CMS Open Payments

12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study

Research payments

$1,260

3 payments

Through program year 2021, $1,260 in research payments was reported against 12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study, across 3 payments, paid by UCB, Inc..

Paid by: UCB, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2021	Research	$1,260	3

Breakdown

Who paid Research payments · program year 2021

UCB, Inc. $1,260 3 payments

Who received the money Research payments · program year 2021

Pavel Klein Neurology · Bethesda, MD $420 1 payment
Jerzy Szaflarski Neurology · Birmingham, AL $420 1 payment
Raymond Faught Neurology · Birmingham, AL $420 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.